Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Epic-Based Clinician Notification, Usual Care; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Ovarian Cancer
Interventions: Fitness Tracker, Social Incentive (Way to Health); Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Polycystic Ovary Syndrome
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 2,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes, Depression
Interventions: Beating the Blues, Escitalopram, Placebo; Behavioral · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 81 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetic Retinopathy
Interventions: Diabetic Patients, Healthy Controls; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetes Mellitus
Interventions: Alogliptin and glyburide, Glyburide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 54
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more

Conditions: Pancreatic Cancer
Interventions: pemetrexed disodium, Radiotherapy; Drug · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: Preference Elicitation; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pre-Diabetes
Interventions: Activity Monitoring-Wrist worn wearable, Activity Monitoring-Waist-worn wearable; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions: Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 37
States / cities: Peoria, Arizona • Chula Vista, California • Concord, California + 34 more

Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
Interventions: GZ17-6.02, Capecitabine; Drug
Lead sponsor: Genzada Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more

Conditions: Digestive Health, Quality of Life
Interventions: Fermented dairy protein with prebiotic fiber supplement, Control placebo; Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Type 1 Diabetes
Interventions: ferumoxytol; Drug
Lead sponsor: Jason Gaglia; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: moxifloxacin hydrochloride, Placebo; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy, Obesity, Diabetes, Healthy Volunteers, Atherosclerosis
Interventions: MR Imaging Techniques - 1, MR Imaging Techniques - 2, MR Imaging Techniques - 3, MR Imaging Techniques - 4; Device
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer, Uterine Cancer
Interventions: fosaprepitant, aprepitant, Oral Placebo, IV placebo; Drug · Other
Lead sponsor: Gynecologic Oncology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: PreDiabetes, Blood Glucose, High
Interventions: Cinnamon, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes Mellitus
Interventions: LCQ908A, Placebo, Sitagliptin, metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 48
States / cities: Mesa, Arizona • Little Rock, Arkansas • Buena Park, California + 39 more

Conditions: Type 2 Diabetes
Interventions: LY2189102, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 18
States / cities: Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Closed Loop Control (CLC), Open Loop; Device
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Post-Surgical Hypoparathyroidism
Interventions: encaleret; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overweight and Obesity, Diabetes, Hypertension, Dyslipidemias, Cardiovascular Diseases
Interventions: PAI; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Neutral Protamine Hagedorn (NPH), Detemir insulin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes
Interventions: Continuous glucose monitor; Device
Lead sponsor: Chieh Chen; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Syracuse, New York

Search by objective public record fields.

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer

The Genetics of Polycystic Ovarian Syndrome

Depression-Diabetes Mechanisms: Urban African Americans

Vascular Reparative Mechanism in Diabetes

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

The Treatment Preferences of Women Diagnosed With Ovarian Cancer

Prediction Using Connected Technologies for Diabetes

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

Imaging of Type 1 Diabetes Progression

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

New Heart Imaging Techniques to Evaluate Possible Heart Disease

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Investigation of Cinnamon Spice on Glucose Tolerance in Subjects With Pre-diabetes

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

A Study of LY2189102 in Patients With Type 2 Diabetes

Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus

PTH-independent Effects of Encaleret

Personal Activity Intelligence (PAI) Pilot

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

Evaluation of a Single Center Expansion of Continuous Glucose Monitor Access in Patients With Type 2 Diabetes